Two of three commonly prescribed non-vitamin K oral anticoagulants (NOACs)—dabigatran and apixaban—have similar rates of major bleeding compared with aspirin, a large systematic review and ...
Similar risks seen for apixaban and dabigatran vs aspirin, while rates were higher for rivaroxaban. HealthDay News — Rates of major bleeding and intracranial hemorrhage are similar for apixaban and ...
The anticoagulants apixaban and dabigatran do not cause more bleeding than aspirin when treating stroke or atrial fibrillation, according to an analysis of randomized clinical trials published in ...
Please provide your email address to receive an email when new articles are posted on . Rivaroxaban was linked to higher rates of major bleeding compared with low-dose aspirin. Apixaban and dabigatran ...
Below please find summaries of new articles that will be published in the next issue of Annals of Internal Medicine. The summaries are not intended to substitute for the full articles as a source of ...
The Food and Drug Administration has granted Alembic permission for Dabigatran Etexilate Capsules, 110 mg, which is the generic of Boehringer Ingelheim’s Pradaxa. Dabigatran Etexilate capsules 110 mg ...
TUESDAY, Feb. 11, 2025 (HealthDay News) -- Rates of major bleeding and intracranial hemorrhage are similar for apixaban and dabigatran versus aspirin, while rates are higher for rivaroxaban, according ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results